Sage Therapeutics Parkinson’s treatment drug failed in a midstage study, with the company’s stock collapsing to a record low. Sage has decided to stop developing dalzanemdor for Parkinson’s disease patients, and will focus its efforts on Alzheimer’s and Huntington’s disease.